Results 81 to 90 of about 2,622 (185)

Clear Cell Renal Carcinoma in an Ulcerative Colitis Patient Under Short-Term Immunosuppressive Therapy: A Case Report

Clinics and Practice
Background/Objectives: Renal cell cancer is a rare occurrence in patients with ulcerative colitis (UC), with no clearly demonstrated association between UC and an increased risk of renal malignancies.
Raffaele Pellegrino, Giuseppe Imperio, Michele Izzo, Ilaria De Costanzo, Fabio Landa, Paola Ciamarra, Marco Niosi, Antonietta Gerarda Gravina, Alessandro Federico   +8 more
doaj   +1 more source

JAK Inhibitor and Crohn’s Disease

Biomedicines
Crohn’s disease is a chronic inflammatory granulomatous disease of the gastrointestinal tract. The global incidence and prevalence of Crohn’s disease have significantly increased, largely due to genetic susceptibility, environmental changes, and ...
Mengyan Xu, Shi Wang, Sanping Xu, Rui Gong   +3 more
doaj   +1 more source

[Cost per Responder Analysis of Filgotinib in Patients Suffering from Ulcerative Colitis] [PDF]

OBJECTIVE: To evaluate the costs and benefits associated with the use of biologics and Janus kinase inhibitors (JAKi) for the treatment of bio-experienced patients suffering from ulcerative colitis in Italy.METHODS: This pharmacoeconomic analysis ...
Pradelli, Lorenzo, Povero, Massimiliano, Castello, Luca, Visentin, Elena   +3 more
core   +2 more sources

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Drugs in Context, 2019
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by joint involvement, extra-articular manifestations, comorbidities, and increased mortality.
Martina Biggioggero, Andrea Becciolini, Chiara Crotti, Elena Agape, Ennio Giulio Favalli   +4 more
doaj   +1 more source

Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial [PDF]

IMPORTANCE: Noninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options. OBJECTIVE: To assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment ...
Dick, Andrew D, Dacey, Mark S, Guo, Ying, Sharma, Sumit, Shah, Rajiv E, Suhler, Eric B, Grewal, Dilraj S, Genovese, Mark C, Faia, Lisa J, Nguyen, Quan Dong, Srivastava, Sunil K, Barchuk, William T, Besuyen, Robin, Rosenbaum, James T, Scales, David K, Watkins, Timothy R, Chu, David S   +16 more
core  

Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody [PDF]

Intestinal Research
Background/Aims Tofacitinib (TFB), filgotinib (FIL), and upadacitinib (UPA) are Janus kinase (JAK) inhibitors approved for moderate-to-severe ulcerative colitis (UC).
Maiko Ikenouchi, Hirokazu Fukui, Soichi Yagi, Akira Nogami, Koji Kaku, Toshiyuki Sato, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Tetsuya Takagawa, Toshihiko Tomita, Taku Kobayashi, Shinichiro Shinzaki   +12 more
doaj   +1 more source

State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review

Pharmaceuticals
Background/Objectives: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation and incomplete response to conventional therapies.
Yunseok Choi, Suhyun Lee, Hyeon Ji Kim, Taemin Park, Won Gun Kwack, Seungwon Yang, Eun Kyoung Chung   +6 more
doaj   +1 more source

Correction to: Filgotinib: First Approval [PDF]

Drugs, 2021
Dhillon, Sohita, Keam, Susan J.
openaire   +1 more source

Ustekinumab i filgotinib per al tractament de la colitis ulcerosa en pacients adults [PDF]

, 2022
Colitis ulcerosa; Ustekinumab; Filgotinib; Anticòs monoclonalColitis ulcerosa; Ustekinumab; Filgotinib; Anticuerpo monoclonalUlcerative colitis; Ustekinumab; Filgotinib; Monoclonal antibodyLa colitis ulcerosa (CU) és una malaltia inflamatòria intestinal (
Programa d'Harmonització Farmacoterapèutica
core  

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate [PDF]

Objectives: Clinical trials restricted to moderately active RA are limited. Filgotinib is approved for treating moderate to severe active RA. This post hoc analysis assessed efficacy and safety of filgotinib in moderately active RA.
Taylor, Peter C, Buch, Maya H, Akroyd, Laura, Walker, David, Barry, Jane, Omoruyi, Edmund V Ekoka, Edwards, Christopher J   +6 more
core   +2 more sources